Arvinas, Inc. (ARVN) vs Capricor Therapeutics, Inc. (CAPR)
A side-by-side comparison of Arvinas, Inc. and Capricor Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARVN
Arvinas, Inc.
$7.42HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
CAPR
Capricor Therapeutics, Inc.
$7.70HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — ARVN vs CAPR
growth of $100 · dividends reinvested · last 8yARVN -53.5% (-9.1%/yr)CAPR -30.5% (-4.5%/yr)CAPR compounded faster over this window
ARVN CAPR
ARVN vs CAPR: by the numbers
- •ARVN is the larger company ($479M vs $443M market cap).
- •ARVN is profitable (2.94% net margin) while CAPR runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ARVN | CAPR |
|---|---|---|
| P/E ratio | 46.37 | N/A |
| P/S ratio | 1.51 | N/A |
| P/B ratio | 0.85 | 1.80 |
| EV / EBITDA | N/A | 0.44 |
Profitability
| Metric | ARVN | CAPR |
|---|---|---|
| Gross margin | 96.43% | 0.00% |
| Operating margin | -43.75% | 0.00% |
| Net margin | 2.94% | 0.00% |
| ROE | 1.65% | -52.56% |
| ROIC | -2.19% | -40.25% |
Growth (annualized)
| Metric | ARVN | CAPR |
|---|---|---|
| Revenue CAGR (5Y) | 72.38% | N/A |
| Total return CAGR (5Y) | -38.16% | 15.17% |
Frequently asked
- Is ARVN or CAPR more profitable?
- ARVN runs the higher net margin — ARVN at 2.94% versus CAPR at 0.00%.
- How have ARVN and CAPR total returns compared?
- Over the past 5 years, ARVN delivered -38.16% and CAPR delivered 15.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arvinas P/E ratioArvinas ROECapricor Therapeutics ROEArvinas operating marginCapricor Therapeutics operating marginArvinas revenue growthCapricor Therapeutics revenue growthArvinas free cash flowCapricor Therapeutics free cash flow
Arvinas & Capricor Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.